CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,221 enrolled
Drug / intervention
CDB-2914 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00551616
NCT00551616Phase 3Completed
CompareCT.gov

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

HRA Pharma·interventional·Posted Oct 31, 2007·Updated May 3, 2022

In Brief

A Phase 3 clinical trial evaluating CDB-2914 and Levonorgestrel for Contraception. Completed, enrolled 2,221 participants across 33 sites in 3 countries.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesIreland, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 31, 2007
Enrollment StartApr 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.7 years ago

Interventions

CDB-2914drug

Single dose

Levonorgestreldrug

Single dose